Cefadroxil Market size was valued at USD 340.4 million in 2024 and is anticipated to surpass USD 526.4 million by 2037, registering a CAGR of 3.7% during the forecast timeline i.e. 2025-2037. In 2025, the industry size of cefadroxil is assessed at USD 352.9 million.
Growth in the cefadroxil market has been supported by multiple factors that lie underneath its clinical relevance and therapeutic advantages. Bacterial infections are rising alarmingly, calling for effective antibiotics, such as cefadroxil, to achieve a stable treatment outcome. For instance, in Dec 2022, a total of 7.7 million deaths around the world were reported to be caused by bacterial infection, except tuberculosis. That makes 13.6%, or 1 in 8, of all deaths worldwide. Therefore, it emerges that bacterial infections are the second most common cause of death globally.
In addition, the trend of ambulatory care has increased, along with the demand to administer oral antibiotics, thus increasing the cefadroxil market share. For instance, in 2018, most Medicare-billed ASCs specialized in only one clinical area, and gastroenterology (21% of all ASCs) and ophthalmology (21% of all ASCs) were the most represented specialties. Altogether, in 2018, 65 percent of all ASCs were single-specialty facilities and 35 percent were multispecialty facilities, offering services in more than one clinical specialty. In addition, 5,717 Medicare-certified ASCs treated 3.5 million fee-for-service (FFS) Medicare beneficiaries and spending on ASC services was approximately USD 4.9 billion.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
3.7% |
|
Base Year Market Size (2024) |
USD 340.4 million |
|
Forecast Year Market Size (2037) |
USD 526.4 million |
|
Regional Scope |
|
Type (USP, EP)
USP segment is anticipated to account for more than 60.1% cefadroxil market share by the end of 2037, wherein the convenience and cost-effectiveness of an oral formulation form is considered for decision-making. Oral cefadroxil is highly preferred for outpatient treatment of mild to moderate bacterial infections, which is an overall shift in the management of infections through oral antibiotics to avoid hospital visits. For instance, in October 2024, Iterum Therapeutics plc announced that the U.S. FDA has approved its new oral drug application for ORLYNVAH for the treatment of uncomplicated urinary tract infections (uUTIs).
Application (Tablet, Capsule)
The tablet segment is anticipated to dominate the cefadroxil market by 2037. The trends for the cefadroxil tablet reflect a continually rising demand to administer this antibiotic to outpatients with a range of bacterial infections. The tablet is used in the treatment of uncomplicated urinary tract infections, skin infections, and respiratory tract infections, based on its relatively low cost. For instance, in March 2024, EMA gave a positive marketing authorization recommendation for Emblaveo (aztreonam-avibactam) tablet. This was for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia, and infections due to some bacterial strains.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Application |
|
North America Market Statistics
North America cefadroxil market is set to account for revenue share of more than 44.3% by the end of 2037. The region's emphasis on healthcare research, strong pharmaceutical market, and awareness among healthcare professionals are the factors that contribute to the significant usage of Cefadroxil. Furthermore, the prevalence of infectious diseases and an aggressive approach to antibiotic use also add to the region's position as a significant consumer of Cefadroxil.
In the U.S. the cefadroxil market is experiencing a remarkable growth attributable to the presence of state-of-the-art healthcare facilities. In addition, development of combination therapy expands the spectrum of cefadroxil activity and renders the drug effective against pathogens. For instance, in April 2024, Fresenius revealed that it is making the biosimilar version of Actemra (tocilizumab) called Tyenne available immediately in the country. Tyenne is an IV product for use in the treatment of chronic autoimmune diseases.
In Canada, the cefadrolix market is expected to grow rapidly during the projected timeline. The recent advances through research and development toward better compliance with the requirements of the patient have fueled the market growth. For instance, in March 2024, A research team at The Ottawa Hospital treated the first patient in Canada with bacteriophage (phage) therapy. This therapy is given to patients with chronic artificial joint infections known as phages. Thus, through research the country is becoming an opportunist in the market
Asia Pacific Market Analysis
The cefadroxil market in the Asia Pacific is anticipated to grow significantly during the forecast timeline i.e. 2025-2037. The strong presence of hospital pharmacies in the region ensures a smooth transition to outpatient care by dispensing medications at the time of discharge, thus delivering an effective treatment. The increasing production of generic drugs also supports the market as Cefadroxil is usually sold at cheaper prices than other antibiotics. Moreover, a sizeable population base and a growing awareness among people regarding skin health issues and infections boost the market activities.
The cefadrolix market in China is significantly expanding owing to the prompt regulatory approvals in formulations of new drugs. For instance, in May 2024, Zai Lab Limited announced the approval of its new drug application by China's National Medical Products Administration (NMPA) for the use of XACDURO (Sulbactam-Durlobactam). It is used for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults, caused by susceptible isolates of acinetobacter baumannii-calcoaceticus complex in patients over 18 years of age.
The landscape of the cefadrolix market in India is gaining significant traction owing to its conducive regulatory support to improve the healthcare system with the launch of effective drugs. For instance, in November 2024, Nafithromycin was developed with the Biotechnology Industry Research Assistance Council (BIRAC) and was brought to market under the trade name Miqnaf by the Wolkardt. The antibiotic is the country's first indigenously developed for fighting resistant infections against antimicrobial resistance or AMR. It is the first indigenous antibiotic for resistant infections.
Companies by offering their diversified portfolio of high-quality pharmaceutical products in the cefadroxil market. Emphasis on the research and development process, besides quality assurance practices, has made the company guarantee reliable and effective Cefadroxil formulation. Furthermore, strategic collaborations are expanding its market reach in meeting the growing demand for Cefadroxil medications. For instance, in January 2022, Becton, Dickinson, and Company announced a new partnership with Pfizer Inc. and a charitable foundation Wellcome. It aimed at getting a clearer insight into diagnostics for better development in antimicrobial stewardship worldwide.
Here's the list of some key players:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?